Overview
Karuna Therapeutics developed KarXT (xanomeline-trospium), a novel muscarinic receptor-based treatment for schizophrenia that received FDA approval in 2024 under the brand name Cobenfy, representing the first new mechanism of action for schizophrenia in decades. Karuna was acquired by Bristol Myers Squibb in 2024 for approximately $14 billion.
More in Neuropharmaceuticals
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
💊 Neuropharmaceuticals
Location
Boston, USA
Funding
Acquired · Bristol Myers Squibb 2024
Website
www.karunatx.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →